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Abstract
Background: Xenografts have been shown to provide a suitable source of tumor tissue for molecular analysis in
the absence of primary tumor material. We utilized ES xenograft series for integrated microarray analyses to identify
novel biomarkers.
Method: Microarray technology (array comparative genomic hybridization (aCGH) and micro RNA arrays) was used
to screen and identify copy number changes and differentially expressed miRNAs of 34 and 14 passages,
respectively. Incubated cells used for xenografting (Passage 0) were considered to represent the primary tumor.
Four important differentially expressed miRNAs (miR-31, miR-31*, miR-145, miR-106) were selected for further
validation by real time polymerase chain reaction (RT-PCR). Integrated analysis of aCGH and miRNA data was
performed on 14 xenograft passages by bioinformatic methods.
Results: The most frequent losses and gains of DNA copy number were detected at 9p21.3, 16q and at 8, 15,
17q21.32-qter, 1q21.1-qter, respectively. The presence of these alterations was consistent in all tumor passages.
aCGH profiles of xenograft passages of each series resembled their corresponding primary tumors (passage 0). MiR-
21, miR-31, miR-31*, miR-106b, miR-145, miR-150*, miR-371-5p, miR-557 and miR-598 showed recurrently altered
expression. These miRNAS were predicted to regulate many ES-associated genes, such as genes of the IGF1
pathway, EWSR1, FLI1 and their fusion gene (EWS-FLI1). Twenty differentially expressed miRNAs were pinpointed in
regions carrying altered copy numbers.
Conclusion: In the present study, ES xenografts were successfully applied for integrated microarray analyses. Our
findings showed expression changes of miRNAs that were predicted to regulate many ES associated genes, such as
IGF1 pathway genes, FLI1, EWSR1, and the EWS-FLI1 fusion genes.
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Background
Due to active international collaboration in the study of
rare tumors, such as in Ewing’s sarcoma (ES), a great
body of tumor-related molecular biomarkers have
already been mined by novel array technologies and the
clinical significance of some of the biomarkers has been
established [1]. A limiting factor for the research of rare
bone tumors has been the limited availability of research
material derived from patients. Therefore, xenografts,
tumors grown from human tumor cells and implanted
in immunodeficient animals, are a viable option that is
widely used for in vivo models [2,3]. Xenografted tumors
are enriched for neoplastic cells with the minimal con-
taminating mouse stromal tissue, a property that makes
them suitable for molecular analysis [4]. Several studies
have shown that xenograft tumors may provide an accu-
rate reflection of tumor biology [5-9].
MicroRNAs (miRNAs) are small, single-stranded non-
coding endogenous RNAs, consisting of 20-23 nucleo-
tides, typically acting as post-transcriptional repressors
[10,11]. Despite the fact that miRNAs have been impli-
c a t e di nm o r et h a n7 0d i s e a s e s ,t h e yh a v en e v e rb e e n
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H e r e ,w eh a v ep e r f o r m e dm i R N A -a n dc o m p a r a t i v e
genomic hybridization (CGH) array analyses on a series
of ES xenografts to investigate differential miRNA
expression and genomic DNA copy number changes,
which are potentially involved in the tumorigenesis of
ES. These results have been assessed to identify whether
copy number alterations influence miRNA expression,
since DNA copy number abnormalities can have a direct
impact on the miRNA expression levels [13]. Multiple
xenograft passages from each primary tumor were tested
to enhance the statistical power of the study.
Methods
Samples
Originally six xenograft series originating from ES
patients (5 primary tumors and a lung metastasis) com-
prising 34 passages in total were obtained from the
Department of Pathology, University of Valencia, Spain.
Two series of xenograft passages originated from one
patient with both the primary tumor and the metastatic
tumor in the lung. Although all of the 34 passages were
used in the aCGH study, only 14 out the 34 passages
were available for the miRNA study (Table 1). These 14
passages represented original 5 xenograft series, includ-
ing both early and advanced passages. The passage 0
that represented primary tumor and was available for
four series of the xenografts was not, however, available
for miRNA profiling. The EWS-FLI1 and EWS-FEV
translocations were present in 4 and 1 of the primary
tumors, respectively, and were retained in all xenografts.
To select an optimum control for any kind of expression
analysis is generally considered a difficult task; we ended
up with two human mesenchymal stem cell samples
from different cell cultures for use as controls.
Mesenchymal stem cells have been utilized as control
s a m p l e si nm a n yp r e v i o u se x p r e s s i o ns t u d i e sd u et ot h e
convincing evidence that supports the mesenchymal
stem cell origin of ES [13-15]. DNA microarray analysis,
as well as functional studies, have revealed the relation-
ship between ES and mesenchymal stem cells [16,17] as
well as between ES and endothelium, and fetal neural
crest [18,19], further sustaining the fact that, despite all
the efforts, the origin of ES is still a matter of dispute.
Very likely ES derives from much undifferentiated cells.
In our analysis, we used mesenchymal stem cell as the
calibrator, in analogy to other reports recently published
[20,21].
The stem cells were obtained from human primary
bone marrow-derived mesenchymal stem cells after
informed patient consent; precisely, from bone marrow
aspirates (iliac crest) of patients undergoing hip replace-
ment surgery. Nucleated cells were placed in modified
alpha-MEM media (Li StarFish) containing 20% fetal
bovine serum (Cambrex Bioscience), 100 units/mL peni-
cillin (Life Technologies), 100 mg/mL streptomycin (Life
Technologies), and 2 mmol/L glutamax (Life Technolo-
gies). Confluent cells were harvested by trypsin/EDTA
and seeded at 1:3 density.
Xenografts
Male nude mice were purchased from IFFA-CREDO
(Lyon, France) and kept under specific pathogen-free con-
ditions throughout the experiment (with vinyl isolates plus
sterilized food, water, cage, and bedding). The specimens
for xenografting were obtained from the surgery of origi-
nal tumors and placed in the culture medium (RPMI
1640) with antibiotics at 37°C until the transplantation
(usually less than 2 hours after the surgery). Various frag-
ments of the non-necrotic tumor, about 3-5 mm in size,
were xenografted into the subcutaneous tissue of the
backs of nude mice. The cells from this first implantation
are denoted as passage 0 cells and are considered to repre-
sent primary tumors. After allowing the growth to
approximately 2-3 cm, the subsequent tumor transfers
were performed following the same procedures as in the
initial xenotransplant and always under highly sterile con-
ditions. In each passage, sufficient amount of material was
obtained for the histopathology analysis (Formalin-fixed
paraffin-embedded tissue blocks from which tissue micro-
arrays were constructed), the touch preparations, the elec-
tron microscopy, the tissue culture, and frozen tissue. All
the experimentation involving laboratory animals was
approved by the Institutional Animal Care of Valencia
University and the Local Government and was performed
in accordance with the national legislation of Spain.
T h ep l o i d ya n a l y s i sw a sn o ts e e nn e c e s s a r yt ob ep e r -
formed as both histopathological and copy number ana-
lysis did not provide any evidence of polyploidy.
Nucleic acid isolation
Genomic DNA from the 34 passages (Table 1) was
extracted by the standard phenol-chloroform method.
Table 1 Ewing sarcoma xenograft series, 6, originating
from five patients
Case No. (Nude) Xenograft Passage
488 (15) 1*, 2*, 4, 7*, 11, 14*
445 (22) 0, 1, 4, 11, 15, 22
451 (53) 0, 4, 11*, 15*, 18, 21*
455 (199) 0, 1, 5*, 11, 17, 25*
430 (PRI) (230) 0, 1*, 4, 9, 19*
430 (MET) (248) 1*, 4, 14*, 21, 30*
Case number 430 has two xenograft passages originating from one patient in
different status of tumor: PRI = Primary Tumor, MET = Lung Metastasis.
Samples used in the miRNA study are marked with an asterisk. Xenograft
passage number 0 refers to the corresponding primary patient sample
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Page 2 of 12Reference DNAs, male and female, were extracted from
the pooled blood samples (4 individuals each) obtained
from the Blood Service, Red Cross, Finland. The Qia-
gen’s miRNeasy Mini Kit (Qiagen, Valencia, CA, USA)
was used to extract total RNA, including miRNA,
according to the manufacturer’s instructions. The Nano-
drop-1000 spectrophotometer (Thermo Fisher Scientific
Inc., Wilmington, DE, USA) was used for quantification
of DNA and RNA. The quality of DNA was checked by
gel electrophoresis, while for the quality of total RNA
and miRNA, the Agilent bioanalyzer (Agilent Technolo-
gies, Santa Clara, CA, USA) was applied.
Array CGH hybridization, scanning and data analysis
The Agilent Human Genome CGH 4x44A oligo micro-
arrays (Agilent Technologies, Santa Clara, CA, USA)
containing ~44,000 oligonucleotide probes were used.
Digestion, labeling, and hybridization of DNA were
done according to the manufacturer’si n s t r u c t i o n s( A g i -
lent protocol version 2.0). Briefly, the same amounts
(1.5 μg) of patient DNA and gender matched reference
DNA were digested. The digested DNAs were labelled
by random priming with Cy3-dUTP (reference DNA)
and Cy5-dUTP (patient DNA) by use of the Agilent
Labelling Kit, after which the labelled DNAs were puri-
fied. Next, differentially labelled patient and reference
DNAs were combined and hybridized to Agilent Human
Genome CGH 4x44A microarrays at 65°C for 24 hours.
The hybridized arrays were washed and, then, scanned
with the Agilent’s microarray scanner (G2565BA, Agi-
lent Technologies, Santa Clara, CA, USA). The raw data
was extracted from the array images by the Agilent’s
Feature Extraction Software (version 8.1). The data was
analyzed with the Agilent CGH Analytics software (ver-
sion 3.4) using ADM-2 algorithm (threshold 6.0) with
1.0 Mb window size.
MicroRNA hybridization, scanning and data processing
We used the Agilent’s miRNA microarray system (V3),
containing 866 human and 89 human viral miRNAs cata-
logued in the Sanger miRNA database v12 (Agilent Tech-
nologies, Santa Clara, CA, USA). Labelling and
hybridization of RNA samples was performed with the
Agilent’s miRNA Complete Labelling and Hyb Kit.
Accordingly, 100 ng of total RNA were treated with Calf
Intestine Phosphatase for 30 min at 37°C; 100% DMSO
was used for denaturation at 100°C for 5 min, after which
the samples were immediately transferred into an ice
water bath to prevent reannealing. Next, samples were
labelled with cyanine 3-pCp by incubating with T4 RNA
ligase for 2 hours at 16°C. After the labeling reaction, the
samples were vacuum dried at medium heat and re-sus-
pended in nuclease-free water. Next, samples were hybri-
dized to the microarrays in the Agilent SureHyb
chambers (Agilent Technologies) for 20 hours at 55°C,
after which the microarrays were washed with the manu-
facturer’s washing buffers. The arrays were scanned using
the Agilent’s scanner and the raw data were preprocessed
with the Agilent’s Feature Extraction Software with
default parameters. Details of the miRNA preprocessing
protocol are provided by the manufacturer.
Statistical analysis was carried out with the Gene-
Spring GX analysis software (version 10) and the R sta-
tistical programming language (http://www.r-project.
org). The data were preprocessed by adding offsets and
carrying out normalization between all the arrays by the
quantile method, and taking log2 transformation. The
data were filtered by removing control miRNAs and the
miRNAs that were not detected across any of the sam-
ples. Detection calls were provided by the Agilent’sF e a -
ture Extraction Software. MiRNAs with less than the
threshold of the ratio of total gene signal/total gene
error under three were considered to be undetected.
The detected miRNAs were regarded as present in the
measured sample. We also removed miRNAs based on
their expression: for each miRNA, its expression had to
exceed in at least one array (negative control miRNAs’
expression) + 1.5× standard deviation (negative control
miRNAs’ expression). We examined the detection calls
for each sample to determine which miRNAs were
expressed or not expressed. To find differentially
expressed miRNAs between controls and xenograft sam-
ples, we performed moderated t-tests for each miRNA
to find significant differences in miRNA expression
between the two groups and, then, calculated the most
significant up-regulated and downregulated miRNAs
(adjusted p value [q value] < 0.05, Bonferroni correction
to correct for multiple testing).
Real-time polymerase chain reaction (real-time RT-PCR)
analysis
To validate the selected miRNA expression levels in ES
samples compared to control samples, RT-PCR analysis
was applied. The miScript Reverse Transcription Kit
(Qiagen, Valencia, CA) served for reverse transcription
of RNA, according to manufacturer’s guidelines. QRT-
PCR was performed on a Light-cycler, software v.3.5
(Roche Applied Science, Mannheim, Germany) by the
SYBR Green miScript PCR system (Qiagen). Each reac-
tion was performed in a 20-μl volume with 5 ng tem-
plate cDNA. The primers for amplification of selected
miRNAs and snRNA U6 were purchased from the Qia-
gen. The experiments were performed in duplicate for
each RNA sample, and every run included a control
without template. The U6 primer assay (Qiagen) served
as an endogenous control for normalization. The relative
quantification (RQ) for each miRNA, compared with U6
was calculated using equation 2
-ΔΔCt.
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We investigated whether any association existed
between miRNA expression changes and gain/loss of
genomic regions. We mapped each miRNA to its chro-
mosomal band location, which was retrieved from the
Ensembl, using the biomaRt package, and the mirBase
database. For each miRNA, we counted the number of
xenograft samples (out of 14) in which there was loss,
gain, or no change in copy number for the correspond-
ing chromosomal band. Possible associations were deter-
mined by counting the number of samples showing
miRNA over-expressed/genomic gain and miRNA
under-expressed/genomic loss. We also counted the
number of control samples (out of 2) in which the
miRNA was detected.
Predicted targets of differentially expressed miRNAs
After having acquired the differentially expressed miR-
NAs, we used the miRBase target prediction database
(http://microrna.sanger.ac.uk), TargetScan (http://www.
targetscan.org), and miRanda (http://www.microRNA.
org) for evaluation of the predicted mRNA targets. The
list of predicted mRNA targets was screened for the
genes known to be functionally relevant in ES and pre-
dicted at least by one of the algorithms.
Results
Copy number alterations in xenografts
By the aCGH analysis, xenograft passages displayed a
total of 28 copy number changes, of which approxi-
mately half appeared in every passage of each series
whilst the other half were present in some of the pas-
sages of each series (Table 2, and 3). All these changes
were evident in passage 0. Moreover, the clustering ana-
lysis of aCGH profiles for each cytogenetic location indi-
cated that the aCGH profiles of the passages 0 as
primary tumors and the rest of the xenograft passages
were similar (Figure 1). Copy number losses (65%) were
more frequent than gains (35%). The most frequent
copy number losses were seen at chromosomal regions
9p21.3 and 16q; these were observed in four (63%) and
two (20%) series of xenografts passages, respectively.
T h ef r e q u e n tg a i na tw h o l ec h r o m o s o m e s8a n d1 5
(17%) occurring together with a gain at 17q21.32-qter
(17%) was observable in all passages of a series (case
number 445). The genomic region 1q21.1-qter fre-
quently displayed gain. Changes in copy number were
acquired during the growth period of xenografts includ-
ing gains at 2q35-q37.3, 4q13.3-qter, 8p11.21-p21.2 and
8q and losses at 8p, 17p, 13, Xq21.1, 1p13.3-p31.1, 5q,
11q13.4-q24.3, Xq12-q26.3 and 16q. In one xenograft
series (Case number 488), loss of 17q12-q21.32, that
was present in the early passages, disappeared during
the growth process. The loss of 1p36.12-pter in the first
two passages originating from lung metastasis (1 and 4)
changed to loss of 1p36.21-pter in the last three pas-
sages (14, 21, and 30). The lung metastasis xenografts
showed 9 copy number changes, whereas only 3 of these
aberrations were observable in the xenograft passages
from its primary tumor.
MicroRNA alterations in xenografts
Differences in miRNA expression between xenografts and
control samples were detected upon analysis (Figure 2).
Exclusively expressed miRNAs were detected; two in con-
trol samples (miR-31, miR-31*) and 46 in all xenograft
passages (Table 4). In addition, 5 miRNAs (miR-106b,
miR-93, miR-181b, miR-101, miR-30b) were significantly
over-expressed (q-value < 0.05), while 6 miRNAs (miR-
145, miR-193a-3p, miR-100, miR-22, miR-21, miR-574-3p)
were significantly under-expressed across the xenograft
passages in relation to the controls (q-value < 0.05). Xeno-
grafts from primary and control samples were compared
to xenograft passages from the lung metastasis (Case num-
ber 430), to determine differences in miRNA expression. A
set of 30 miRNAs were found to have differential expres-
sion; 18 exclusively expressed in lung metastatics xeno-
grafts and 12 in primary tumor xenografts.
Table 2 The copy number changes present in all the
passages of each xenograft series
Case No. (Nude) Array CGH results
488 (15) +1q21.1-qter, -13q14.12-qter
445 (22) -2q35-q37.3 (uncontinuous), + 8, +15, +17q21.32-qter
451 (53) -1q24.3-q25.2, - 3p12.3-p24.3, -9p21.3
455 (199) +1q, -16q, -9p21.3
430 (PRI) (230) -9p21.3
430 (MET) (248) -1p36.12-pter, -9p21.3
PRI = Primary Tumor, MET = Lung Metastasis
Table 3 Copy number changes present in only part of
the passages of each xenograft series
Case Nude- Passage Array CGH result
488 15- 2, 4, 7, 11, 14 -2q35-q37.3
488 15- 1, 2, 4, 7 -17q12-q21.32
488 15- 14 +17
451 53- 11, 15,18, 21 +4q13.3-qter, -17p
455 199- 5, 11, 17, 25 -13
455 199- 25 -Xq21.1
430 (PRI) 230- 1, 4, 9, 19 +8p11.21-p21.2, +8q
430 (MET) 248- 1, 4 -1p36.12-pter
430 (MET) 248- 14, 21, 30 -1p36.21-pter, -1p13.3-p31.1, -5q,
-11q13.4-q24.3, -Xq12-q26.3
430 (MET) 248- 21, 30 +8p11.21-p21.2, +8q
430 (MET) 248- 30 -16q
PRI = Primary Tumor, MET = Lung Metastasis
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Page 4 of 12Eleven miRNAs were expressed in both control sam-
ples and primary tumor xenograft passages but not at
all in metastatic samples (Table 5, Figure 3). Nine of
these (miR-214*, miR-154*, miR-337-3P, miR-369-5p,
miR-409-5p, miR-411, miR-485-3p, miR-487a, miR-770-
5p) were also preferentially expressed in other primary
tumor xenografts when compared to metastatic xeno-
graft passages.
Validation of differentially expressed miRNAs by qRT-PCR
QRT-PCR was used to validate the expression levels of
four selected miRNAs that showed altered expression in
Figure 1 Copy number changes on each chromosome were ordered using hierarchical clustering. Most of the xenograft passages of each
series clustered together and also with the passage 0, its corresponding primary tumor.
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Page 5 of 12the miRNA microarray results. The selection of miRNAs
for further validation was based on the expression level
of miRNA microarray results and on the level of repre-
sentation in the expression categories observed (i.e.
exclusively expressed, significantly under-expressed and
significantly over-expressed). The miR-31 and miR-31*
were exclusively expressed in control samples and
absent in xenograft passages, while miR-106b was
Figure 2 This picture shows the miRNAs detected in metastasis and corresponding primary tumor xenograft passages and control
samples. In common, these three sample types comprised 191 miRNAs. In addition to these, 98 miRNAs were expressed in both the metastasis
and the corresponding primary tumor xenograft passages, 22 miRNAs were exclusively expressed in metastatic xenograft passages, 12 miRNAs
were exclusive to xenografts from primary tumor, and 11 miRNAs were expressed as well in controls as in primary tumor xenograft passages.
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Page 6 of 12significantly over-expressed and miR-145 significantly
under-expressed, respectively, in xenograft samples com-
pared to control samples.
As for the validation results by qRT-PCR, the expres-
sion levels of miR-31, miR-31* and miR-145 were
under-expressed in the xenograft samples compared to
the control samples (relative expression 0.00062,
0.00809 and 0.09111, respectively). These results are
consistent with the miRNA microarray results. Simi-
larly, the over-expression of miR-106b in xenograft
samples seen in miRNA microarray was confirmed by
qRT-PCR results showing relative expression level of
87.7.
Relationship between miRNAs and copy number
alterations
A joint analysis of the aCGH data and miRNA data for
the 14 xenograft passages, which were common to both
studies, was performed by looking for miRNAs whose
expression was correlated with a change (loss/gain) at
their chromosomal location. Three criteria were used to
determine the miRNAs of greatest interest: (i) differen-
tially expressed miRNAs in all 14 xenograft passages, (ii)
altered miRNAs whose chromosomal locations were
affected by the same copy number changes in most of
the passages, and (iii) miRNAs fulfilling both previous
criteria.
Of the 46 miRNAs exclusively expressed in all xenograft
passages, 7 miRNAs (miR-144, miR-195*, miR-215, miR-
451, miR-454, miR-557, miR-744) were located in chro-
mosomal regions with a copy number gain in at least one
of the passages. Four miRNAs that displayed absent or
severely reduced expression in any xenograft passages
(miR-22, miR-31, miR-31*, miR-145) were located in chro-
mosomal regions with a copy number loss in at least 2 of
the passages. In addition, five passages displayed gains of a
chromosomal region that contained 3 frequently expressed
miRNAs (miR-765, miR-135b and miR-29c*); miR-765
and miR-135b were expressed in 10 passages while miR-
29c* was expressed in 12 passages but in none of the con-
trol samples (Table 6).
Discussion
Here we have sought to identify differentially expressed
miRNAs in ES xenografts and to investigate the
Table 4 The 46 miRNAs detected in all xenografts
samples, while absent from all control samples.
miRNA miRNA miRNA miRNA
hsa-miR-1224-5p hsa-miR-451 hsa-miR-188-5p hsa-miR-629*
hsa-miR-126* hsa-miR-483-5p hsa-miR-652 hsa-miR-663
hsa-miR-1290 hsa-miR-486-5p hsa-miR-19b-1* hsa-miR-7-1*
hsa-miR-1300 hsa-miR-194 hsa-miR-215 hsa-miR-744
hsa-miR-135a* hsa-miR-195* hsa-miR-219-5p hsa-miR-877*
hsa-miR-142-3p hsa-miR-501-3p hsa-miR-873 hsa-miR-9
hsa-miR-144 hsa-miR-502-3p hsa-miR-30c-1* hsa-miR-9*
hsa-miR-150 hsa-miR-505* hsa-miR-328
hsa-miR-150* hsa-miR-223 hsa-miR-338-3p
hsa-miR-181c* hsa-miR-564 hsa-miR-371-5p
hsa-miR-548c-5p hsa-miR-421 hsa-miR-345
hsa-miR-557 hsa-miR-339-3p hsa-miR-378
hsa-miR-33a hsa-miR-598 hsa-miR-629
Table 5 MiRNAs expressed in xenograft passages of A) Case 430 primary tumor while absent in lung metastasis, 12
miRNAs, B) Case 430 lung metastasis while absent in primary tumor, 18 miRNAs and C) Case 430 primary tumors and
control, while absent in lung metastasis, 11 miRNAs
miRNAs expressed in
A) Xenograft passages from Primary tumor (12
miRNAs)
B) Xenograft passages
from lung metastasis (18
miRNAs)
C) Control and xenograft passages from Primary tumor (11
miRNAs)
hsa-miR-1237 hsa-miR-1183 hsa-miR-595 hsa-miR-154*
hsa-miR-139-3p hsa-miR-124 hsa-miR-601 hsa-miR-214*
hsa-miR-139-5p hsa-miR-1471 hsa-miR-623 hsa-miR-337-3p
hsa-miR-202 hsa-miR-32* hsa-miR-662 hsa-miR-34a*
hsa-miR-30b* hsa-miR-424* hsa-miR-664* hsa-miR-369-5p
hsa-miR-450a hsa-miR-486-
3p
hsa-miR-671-
5p
hsa-miR-409-5p
hsa-miR-490-3p hsa-miR-
520b
hsa-miR-411
hsa-miR-501-5p hsa-miR-520e hsa-miR-485-3p
hsa-miR-502-5p hsa-miR-96 hsa-miR-487a
hsa-miR-548 d-5p hsa-miR-877 hsa-miR-542-3p
hsa-miR-602 hsa-miR-95 hsa-miR-770-5p
hsa-miR-885-5p hsa-miR-765
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results with aCGH analysis of the same samples.
MiRNA expression profile of ES xenografts
Xenografts displayed 60 differentially expressed miRNAs
that distinguished them from control samples (Human
mesenchymal stem cells). Of these, 46 miRNAs were
exclusively expressed in xenografts while 2 (miR-31 and
miR-31*) miRNAs were exclusively expressed in con-
trols. The remaining 5 miRNAs (miR-106b, miR-93,
miR-181b, miR-101, miR-30b) were significantly over-
expressed while 6 miRNAs (miR-145, miR-193a-3p,
Figure 3 Hierarchical clustering of the xenograft passages. Note that the xenograft passages show a distinct expression profile that
separates them from the mesenchymal stem cell control samples.
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Page 8 of 12miR-100, miR-22, miR-21, miR-574-3p) were signifi-
cantly under-expressed in xenografts. The expression
profiles of 4 miRNAs (miR-31, miR-31*, miR-106b, miR-
145) were confirmed by RT-PCR.
To evaluate the potential role of the differentially
expressed miRNAs, three databases were searched for
the known ES-associated genes targeted by these miR-
NAs, by applying target prediction algorithms. The tar-
gets included EWSR1 (GeneID: 2130), FLI1 (GeneID:
2313), SOX2 (GeneID: 6657), p53 (GeneID: 7157),
IGFBP3 (GeneID: 3486), IGF1 (GeneID: 3479) and
IGF1R (GeneID: 3480). The differential expression of
the miRNAs regulating these genes may play a role in
the tumorigenesis and tumor progression of ES.
Interestingly, miR-150, which targets the tumor sup-
pressor gene TP53, was expressed in all xenograft sam-
ples but in none of the control samples. This is in
accordance with the study of Fabbri and colleagues [22]
who have included TSGs in their investigation of likely
over-expressed miRNA target genes. In addition, one of
our xenograft series (Case number 451) showed losses
at 17p, containing TP53, that appeared in later passages.
Previous ES studies have shown that, despite the low
frequency of mutations in TP53,a na l t e r a t i o no fTP53,
in conjunction with the deletion of CDKN2A,i sa s s o -
ciated with a poor clinical outcome [23,24]. Moreover,
the homozygous deletion of this gene has been reported
in a small subset of ES patients [25,26].
The IGF-1 pathway, whose genes IGF1R, IGF-1 and
IGFBP-3 are among the target genes of the differentially
expressed miRNAs, plays a critical role in cancer devel-
opment, including ES [26-28]. IGF1R is targeted by
miR-145 and miR-31*, and previous studies have show-
nIGF1R to be a direct target of miR-145 [29] as well as
to be over-expressed in Ewing tumors [27,28]. As for
IGF-1, it is the target of 11 miRNAs including miR-21,
miR-31, miR-145, miR-150, miR-194, miR-215, miR-421,
miR-486-5p, 548c-5p, and miR-873. Interestingly,
IGFBP3, which is among the target genes of miR-150*,
was, in our study, expressed in all xenografts but not in
control samples. IGFBP-3, which is a major regulator of
cell proliferation and apoptosis, inhibits the interaction
of IGF-1 with its receptor (IGF1R) [30-33]. Indeed, it
has been reported that high IGF-1 and low IGFBP-3
levels in serum increase the risk of cancer [26]. IGFBP3
is strongly down-regulated by the EWS/FLI-1 fusion
gene [34], which is able to induce expression of embryo-
nic stem cell gene SOX2. Consequently, SOX2 partici-
pates in ES cell proliferation and tumorigenesis and
might play a central role in ES pathogenesis [35]. As for
our study, SOX2 was among the target genes of
miRNA-21 that showed under-expression in xenografts.
Another under-expressed miRNA, miR-145, was pre-
viously found to target FLI1 and its increased expression
leads to a decreased migration of microvascular cells in
response to the growth factor gradients in vitro [36].
Finally, miR-106b targets EWSR1, which undergoes a
chromosomal translocation to produce the EWS-FLI
fusion gene in a majority of ES cases, where it is com-
monly considered to trigger the condition. The action of
miR-106b is, thus, likely to only impact on the original/
unmodified locus for EWSRI since the EWS-FLI lacks
the 3’ portion of EWSR1. Further studies would, natu-
rally, be required to confirm this hypothesis.
The alteration of 41 miRNAs was observed in xeno-
graft passages derived from lung metastatic, which may
play a crucial role in triggering tumor metastasis. Eight
of these miRNAs, all located at the 14q32 imprinted
domain (miR-154*, miR-337-3P, miR-369-5p, miR-409-
5p, miR-411, miR-485-3p, miR-487a, miR-770-5p) were
not expressed in metastasis xenografts but in control
samples, thus suggesting a tumor suppressor function.
Interestingly, gastrointestinal stromal tumors (GISTs)
have displayed 44 expressed miRNAs originatingfrom
Table 6 Altered miRNAs in regions of copy number changes
miRNA in copy number gain miRNA in copy number loss
Chr. Number of samples Chr. Number of samples
miRNA location in gain region miRNA location in loss region
miR-765 1q23.1 5 miR-137 1p21.3 2
miR-135b 1q32.1 5 miR-143* 5q32 2
miR-29c* 1q32.2 5 miR-143* 5q32 2
miR-557 1q24.2 6 miR-145* 5q32 2
miR-215 1q41 6 miR-145 5q32 2
miR-744 17p12 1 miR-31 9p21.3 10
miR-195* 17p13.1 1 miR-31* 9p21.3 10
miR-451 17q11.2 1 miR-22 17p13.3 3
miR-144 17q11.2 1 miR-22* 17p13.3 3
miR-454 17q22 1 miR-503 xq26.3 2
Chr. = Chromosome
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expression of miRNAs was related to tumor progression
[37]. A report by Saito and colleagues [38] suggests that
miRNAs located in this region function as tumor repres-
sor genes and changes in the methylation status of their
promoters could trigger cancer development. This evi-
dence suggests that the miRNAs identified in our study
may act as tumor repressors and their absence could
increase the risk of metastasis and tumor progression in
ES.
Copy number aberrations in ES xenografts
The most recurrent copy number alterations detected in
our CGH analysis (gains at chromosome 8, 1q and
losses at 9p21.3 and 16q) are in agreement with other
findings on ES patients [1,39-46]. The crucial role of
these changes, gains in 1q, 8 and losses of 9p21.3
(including loss of CDKN2A) and 16q, has been clarified
by notable tumor development and adverse clinical out-
come [42,47,48]. These copy number changes were seen
throughout the whole xenograft series. In all passages of
lung metastasis, losses were observed at 1p36.12-pter/
1p36.21-pter. Of note, deletion of this site (1p36) has
been found to be related to a poor clinical outcome in
ES[43,47]. The loss of 1p36.12-pter in the first two pas-
sages originating from lung metastasis (1 and 4) chan-
ged to loss of 1p36.21-pter in the last three passages
(14, 21 and 30). The lung metastasis xenografts showed
9 copy number changes, whereas only 3 of these aberra-
tions were observable in the xenograft passages from its
primary tumor. Likewise in many tumors during the dis-
ease progression, the increase of genomic instability is
also seen here. This instability most probably explains
the variation of the size of 1p deletion. The fact that the
terminal part is retained in the deletion emphasizes the
importance of 1p36.21-pter region in the selection and
in the disease progression.
Somatic mosaicism/heterogeneity occurs commonly in
tumors and plays an important role in the progression
of the tumor and, thereby, can also explain why some
xenograft passages show copy number changes and
others do not.
Integration of miRNA expression profiles and DNA copy
number changes
DNA copy number abnormalities can have a direct
impact on miRNA expression [49]. In the current study,
20 differentially expressed miRNAs were located in the
copy number altered regions. These findings are in
accordance with Calin et al. (2004) who observed that
half of the miRNAs are located in cancer-associated
regions of chromosomes as well as in genomic regions
frequently amplified or lost in cancer [49]. The target
genes for many of the changes are still unknown and,
therefore, miRNAs could well be considered to be the
drivers of the underlying changes.
MiR-31 and miR-31*, targeting IGF1 and IGF1R,a r e
located at the frequently deleted region of 9p21.3, con-
taining the CDKN2A gene, which was frequently lost in
our samples. Under-expression of miR-31 or deletion of
the miR-31 genomic locus is also found in human breast
cancers. This miRNA regulates metastasis by opposing
local invasion and metastatic colonization in this cancer
[50-52]. Chromosome 1 gain is a frequent gain that con-
tains the whole chromosome and seems to be poor
prognostic sign [53]. Interestingly, in our study five
overexpressed miRNAs (miR-765, miR-135b, miR29c,
miR-215, and miR-557) (Table 6) were associated to 1q
gain. These candidate miRNAs have an important role
and could explain the underlying mechanism in ES.
Nevertheless, functional validations of the predicted tar-
get genes are needed to better understand their role in
the ES tumorgnesis.
Conclusions
The current study provides new information about the
miRNA expression and its relationship with the asso-
ciated genomic copy number changes in ES xenografts.
Our findings suggest that miRNAs play a role in the
molecular pathogenesis and tumorigenesis of ES by reg-
ulating important genes in the IGF1 pathway as well as
the genes FLI1, EWSR1,a n dt h eEWS-FLI1 fusion gene.
In addition, integration of the data for gene copy num-
ber changes and miRNA profiles demonstrated some
cases where the differential expression of miRNAs was
t h er e s u l to fc o p yn u m b e ra l t e r a t i o no ft h em i R N A
genomic locus. Moreover, our study showed that the
xenografts can reflect well the genomic pattern of their
original tumor.
Acknowledgements
The study was supported by grants from European Commission (EuroBoNeT
Project LSHC-CT-2006-018814) and the special state subsidy research funds
appropriated to the Helsinki and Uusimaa Hospital District (HUS EVO).
Author details
1Department of Pathology, Haartman Institute and HUSLAB, University of
Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
2Department of Information and Computer Science, Aalto University School
of Science and Technology, Espoo, Finland.
3Department of Pathology,
Universitat de Valencia Studi General, Valencia, Spain.
4Laboratorio di Ricerca
Oncologica, Istituto Ortopedico Rizzoli, Bologna, Italy.
5Laboratory of
Molecular Biology, Fundación Instituto Valenciano de Oncología, Valencia,
Spain.
Authors’ contributions
NM and MG have equally contributed to this study. SK, as a senior
researcher, designed the study and participated in writing the manuscript.
NM performed the laboratory work and participated in writing. SS and TN
performed the array CGH analysis and contributed to the design of the
study plan. MG participated in writing. GL participated in designing the
statistical analysis and preparing the manuscript. EE, US-P, M-LK-J and AR
Mosakhani et al. Journal of Experimental & Clinical Cancer Research 2012, 31:24
http://www.jeccr.com/content/31/1/24
Page 10 of 12participated in designing the study and provided clinical data. All authors
contributed to the manuscript and approved the final version of it.
Competing interests
The authors declare that they have no competing interests.
Received: 18 January 2012 Accepted: 20 March 2012
Published: 20 March 2012
References
1. Savola S, Klami A, Tripathi A, Niini T, Serra M, Picci P, Kaski S, Zambelli D,
Scotlandi K, Knuutila S: Combined use of expression and CGH arrays
pinpoints novel candidate genes in Ewing sarcoma family of tumors.
BMC Cancer 2009, 9:17.
2. Bogner PN, Patnaik SK, Pitoniak R, Kannisto E, Repasky E, Hylander B,
Yendamuri S, Ramnath N: Lung cancer xenografting alters microRNA
profile but not immunophenotype. Biochem Biophys Res Commun 2009,
386:305-310.
3. Mayordomo E, Machado I, Giner F, Kresse SH, Myklebost O, Carda C,
Navarro S, Llombart-Bosch A: A Tissue Microarray Study of Osteosarcoma:
Histopathologic and Immunohistochemical Validation of
Xenotransplanted Tumors as Preclinical Models. Appl Immunohistochem
Mol Morphol 2010, 18:453-461.
4. El-Rifai W, Harper JC, Cummings OW, Hyytinen ER, Frierson HF Jr, Knuutila S,
Powell SM: Consistent genetic alterations in xenografts of proximal
stomach and gastro-esophageal junction adenocarcinomas. Cancer Res
1998, 58:34-37.
5. Neale G, Su X, Morton CL, Phelps D, Gorlick R, Lock RB, Reynolds CP,
Maris JM, Friedman HS, Dome J, Khoury J, Triche TJ, Seeger RC,
Gilbertson R, Khan J, Smith MA, Houghton PJ: Molecular characterization
of the pediatric preclinical testing panel. Clin Cancer Res 2008,
14:4572-4583.
6. Whiteford CC, Bilke S, Greer BT, Chen Q, Braunschweig TA, Cenacchi N,
Wei JS, Smith MA, Houghton P, Morton C, Reynolds CP, Lock R, Gorlick R,
Khanna C, Thiele CJ, Takikita M, Catchpoole D, Hewitt SM, Khan J:
Credentialing preclinical pediatric xenograft models using gene
expression and tissue microarray analysis. Cancer Res 2007, 67:32-40.
7. Hahn SA, Seymour AB, Hoque AT, Schutte M, da Costa LT, Redston MS,
Caldas C, Weinstein CL, Fischer A, Yeo CJ: Allelotype of pancreatic
adenocarcinoma using xenograft enrichment. Cancer Res 1995,
55:4670-4675.
8. Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M,
Merk J: Establishment of patient-derived non-small cell lung cancer
xenografts as models for the identification of predictive biomarkers. Clin
Cancer Res 2008, 14:6456-6468.
9. Perez-Soler R, Kemp B, Wu QP, Mao L, Gomez J, Zeleniuch-Jacquotte A,
Yee H, Lee JS, Jagirdar J, Ling YH: Response and determinants of
sensitivity to paclitaxel in human non-small cell lung cancer tumors
heterotransplanted in nude mice. Clin Cancer Res 2000, 6:4932-4938.
10. Bartels CL, Tsongalis GJ: MicroRNAs: novel biomarkers for human cancer.
Clin Chem 2009, 55:623-631.
11. Winter J, Jung S, Keller S, Gregory RI, Diederichs S: Many roads to maturity:
microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009,
11:228-234.
12. Lu M, Zhang Q, Deng M, Miao J, Guo Y, Gao W, Cui Q: An analysis of
human microRNA and disease associations. PLoS One 2008, 3:e3420.
13. Riggi N, Cironi L, Provero P, Suva ML, Kaloulis K, Garcia-Echeverria C,
Hoffmann F, Trumpp A, Stamenkovic I: Development of Ewing’s sarcoma
from primary bone marrow-derived mesenchymal progenitor cells.
Cancer Res 2005, 65:11459-11468.
14. Castillero-Trejo Y, Eliazer S, Xiang L, Richardson JA, Ilaria RL Jr: Expression of
the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in
EWS/FLI-1-dependent, ewing sarcoma-like tumors. Cancer Res 2005,
65:8698-8705.
15. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O:
Mesenchymal stem cell features of Ewing tumors. Cancer Cell 2007,
11:421-429.
16. Potikyan G, France KA, Carlson MR, Dong J, Nelson SF, Denny CT:
Genetically defined EWS/FLI1 model system suggests mesenchymal
origin of Ewing’s family tumors. Lab Invest 2008, 88:1291-1302.
17. Riggi N, Suva ML, Stamenkovic I: Ewing’s sarcoma origin: from duel to
duality. Expert Rev Anticancer Ther 2009, 9:1025-1030.
18. Richter GH, Plehm S, Fasan A, Rossler S, Unland R, Bennani-Baiti IM,
Hotfilder M, Lowel D, von Luettichau I, Mossbrugger I, Quintanilla-
Martinez L, Kovar H, Staege MS, Muller-Tidow C, Burdach S: EZH2 is a
mediator of EWS/FLI1 driven tumor growth and metastasis blocking
endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci USA
2009, 106:5324-5329.
19. von Levetzow C, Jiang X, Gwye Y, von Levetzow G, Hung L, Cooper A,
Hsu JH, Lawlor ER: Modeling initiation of Ewing sarcoma in human
neural crest cells. PLoS One 2011, 6:e19305.
20. Nakatani F, Ferracin M, Manara MC, Ventura S, Del Monaco V, Ferrari S,
Alberghini M, Grilli A, Knuutila S, Schaefer KL, Mattia G, Negrini M, Picci P,
Serra M, Scotlandi K: miR-34a predicts survival of Ewing’s sarcoma
patients and directly influences cell chemosensitivity and malignancy. J
Pathol 2012, 226:796-805.
21. Ban J, Jug G, Mestdagh P, Schwentner R, Kauer M, Aryee DN, Schaefer KL,
Nakatani F, Scotlandi K, Reiter M, Strunk D, Speleman F, Vandesompele J,
Kovar H: Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved
in a positive feedback loop in Ewing’s sarcoma. Oncogene 2011,
30:2173-2180.
22. Fabbri M, Croce CM, Calin GA: MicroRNAs. Cancer J 2008, 14:1-6.
23. de Alava E, Antonescu CR, Panizo A, Leung D, Meyers PA, Huvos AG, Pardo-
Mindan FJ, Healey JH, Ladanyi M: Prognostic impact of P53 status in
Ewing sarcoma. Cancer 2000, 89:783-792.
24. Huang HY, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healey JH, Wexler LH,
Gorlick R, Meyers P, Ladanyi M: Ewing sarcomas with p53 mutation or
p16/p14ARF homozygous deletion: a highly lethal subset associated
with poor chemoresponse. J Clin Oncol 2005, 23:548-558.
25. Park YK, Chi SG, Kim YW, Park HR, Unni KK: P53 mutations in Ewing’s
sarcoma. Oncol Rep 2001, 8:533-537.
26. Cohen P, Clemmons DR, Rosenfeld RG: Does the GH-IGF axis play a role
in cancer pathogenesis? Growth Horm IGF Res 2000, 10:297-305.
27. Sekyi-Otu A, Bell RS, Ohashi C, Pollak M, Andrulis IL: Insulin-like growth
factor 1 (IGF-1) receptors, IGF-1, and IGF-2 are expressed in primary
human sarcomas. Cancer Res 1995, 55:129-134.
28. Valentinis B, Baserga R: IGF-I receptor signalling in transformation and
differentiation. Mol Pathol 2001, 54:133-137.
29. La Rocca G, Badin M, Shi B, Xu SQ, Deangelis T, Sepp-Lorenzinoi L,
Baserga R: Mechanism of growth inhibition by MicroRNA 145: the role of
the IGF-I receptor signaling pathway. J Cell Physiol 2009, 220:485-491.
30. Cohen P, Lamson G, Okajima T, Rosenfeld RG: Transfection of the human
insulin-like growth factor binding protein-3 gene into Balb/c fibroblasts
inhibits cellular growth. Mol Endocrinol 1993, 7:380-386.
31. Rajah R, Valentinis B, Cohen P: Insulin-like growth factor (IGF)-binding
protein-3 induces apoptosis and mediates the effects of transforming
growth factor-beta1 on programmed cell death through a p53- and IGF-
independent mechanism. J Biol Chem 1997, 272:12181-12188.
32. Schedlich LJ, Young TF, Firth SM, Baxter RC: Insulin-like growth factor-
binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear
transport pathway in T47D human breast carcinoma cells. J Biol Chem
1998, 273:18347-18352.
33. Singh B, Charkowicz D, Mascarenhas D: Insulin-like growth factor-
independent effects mediated by a C-terminal metal-binding domain of
insulin-like growth factor binding protein-3. J Biol Chem 2004,
279:477-487.
34. Prieur A, Tirode F, Cohen P, Delattre O: EWS/FLI-1 silencing and gene
profiling of Ewing cells reveal downstream oncogenic pathways and a
crucial role for repression of insulin-like growth factor binding protein 3.
Mol Cell Biol 2004, 24:7275-7283.
35. Riggi N, Suva ML, De Vito C, Provero P, Stehle JC, Baumer K, Cironi L,
Janiszewska M, Petricevic T, Suva D, Tercier S, Joseph JM, Guillou L,
Stamenkovic I: EWS-FLI-1 modulates miRNA145 and SOX2 expression to
initiate mesenchymal stem cell reprogramming toward Ewing sarcoma
cancer stem cells. Genes Dev 2010, 24:916-932.
36. Larsson E, Fredlund Fuchs P, Heldin J, Barkefors I, Bondjers C, Genove G,
Arrondel C, Gerwins P, Kurschat C, Schermer B, Benzing T, Harvey SJ,
Kreuger J, Lindahl P: Discovery of microvascular miRNAs using public
gene expression data: miR-145 is expressed in pericytes and is a
regulator of Fli1. Genome Med 2009, 1:108.
Mosakhani et al. Journal of Experimental & Clinical Cancer Research 2012, 31:24
http://www.jeccr.com/content/31/1/24
Page 11 of 1237. Haller F, von Heydebreck A, Zhang JD, Gunawan B, Langer C, Ramadori G,
Wiemann S, Sahin O: Localization- and mutation-dependent microRNA
(miRNA) expression signatures in gastrointestinal stromal tumours
(GISTs), with a cluster of co-expressed miRNAs located at 14q32.31. J
Pathol 2010, 220:71-86.
38. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, Jones PA:
Specific activation of microRNA-127 with downregulation of the proto-
oncogene BCL6 by chromatin-modifying drugs in human cancer cells.
Cancer Cell 2006, 9:435-443.
39. Armengol G, Tarkkanen M, Virolainen M, Forus A, Valle J, Bohling T, Asko-
Seljavaara S, Blomqvist C, Elomaa I, Karaharju E, Kivioja AH, Siimes MA,
Tukiainen E, Caballin MR, Myklebost O, Knuutila S: Recurrent gains of 1q, 8
and 12 in the Ewing family of tumours by comparative genomic
hybridization. Br J Cancer 1997, 75:1403-1409.
40. Tarkkanen M, Kiuru-Kuhlefelt S, Blomqvist C, Armengol G, Bohling T,
Ekfors T, Virolainen M, Lindholm P, Monge O, Picci P, Knuutila S, Elomaa I:
Clinical correlations of genetic changes by comparative genomic
hybridization in Ewing sarcoma and related tumors. Cancer Genet
Cytogenet 1999, 114:35-41.
41. Brisset S, Schleiermacher G, Peter M, Mairal A, Oberlin O, Delattre O,
Aurias A: CGH analysis of secondary genetic changes in Ewing tumors:
correlation with metastatic disease in a series of 43 cases. Cancer Genet
Cytogenet 2001, 130:57-61.
42. Ozaki T, Paulussen M, Poremba C, Brinkschmidt C, Rerin J, Ahrens S,
Hoffmann C, Hillmann A, Wai D, Schaefer KL, Boecker W, Juergens H,
Winkelmann W, Dockhorn-Dworniczak B: Genetic imbalances revealed by
comparative genomic hybridization in Ewing tumors. Genes
Chromosomes Cancer 2001, 32:164-171.
43. Lopez-Guerrero JA, Machado I, Scotlandi K, Noguera R, Pellin A, Navarro S,
Serra M, Calabuig-Farinas S, Picci P, Llombart-Bosch A: Clinicopathological
significance of cell cycle regulation markers in a large series of
genetically confirmed Ewing’s Sarcoma Family of Tumors. Int J Cancer
2011, 128:1139-1150.
44. Lopez-Guerrero JA, Pellin A, Noguera R, Carda C, Llombart-Bosch A:
Molecular analysis of the 9p21 locus and p53 genes in Ewing family
tumors. Lab Invest 2001, 81:803-814.
45. Amiel A, Ohali A, Fejgin M, Sardos-Albertini F, Bouaron N, Cohen IJ, Yaniv I,
Zaizov R, Avigad S: Molecular cytogenetic parameters in Ewing sarcoma.
Cancer Genet Cytogenet 2003, 140:107-112.
46. Ferreira BI, Alonso J, Carrillo J, Acquadro F, Largo C, Suela J, Teixeira MR,
Cerveira N, Molares A, Gomez-Lopez G, Pestana A, Sastre A, Garcia-Miguel P,
Cigudosa JC: Array CGH and gene-expression profiling reveals distinct
genomic instability patterns associated with DNA repair and cell-cycle
checkpoint pathways in Ewing’s sarcoma. Oncogene 2008, 27:2084-2090.
47. Hattinger CM, Rumpler S, Strehl S, Ambros IM, Zoubek A, Potschger U,
Gadner H, Ambros PF: Prognostic impact of deletions at 1p36 and
numerical aberrations in Ewing tumors. Genes Chromosomes Cancer 1999,
24:243-254.
48. Huang HY, Illei PB, Zhao Z, Mazumdar M, Huvos AG, Healey JH, Wexler LH,
Gorlick R, Meyers P, Ladanyi M: Ewing sarcomas with p53 mutation or
p16/p14ARF homozygous deletion: a highly lethal subset associated
with poor chemoresponse. J Clin Oncol 2005, 23:548-558.
49. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S,
Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM: Human microRNA
genes are frequently located at fragile sites and genomic regions
involved in cancers. Proc Natl Acad Sci USA 2004, 101:2999-3004.
50. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, Liang S,
Naylor TL, Barchetti A, Ward MR, Yao G, Medina A, O’brien-Jenkins A,
Katsaros D, Hatzigeorgiou A, Gimotty PA, Weber BL, Coukos G: microRNAs
exhibit high frequency genomic alterations in human cancer. Proc Natl
Acad Sci USA 2006, 103:9136-9141.
51. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY:
MicroRNA miR-21 overexpression in human breast cancer is associated
with advanced clinical stage, lymph node metastasis and patient poor
prognosis. RNA 2008, 14:2348-2360.
52. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, Wang ZC,
Brock JE, Richardson AL, Weinberg RA: A pleiotropically acting microRNA,
miR-31, inhibits breast cancer metastasis. Cell 2009, 137:1032-1046.
53. Mackintosh C, Ordonez JL, Garcia-Dominguez DJ, Sevillano V, Llombart-
Bosch A, Szuhai K, Scotlandi K, Alberghini M, Sciot R, Sinnaeve F,
Hogendoorn PC, Picci P, Knuutila S, Dirksen U, Debiec-Rychter M,
Schaefer KL, de Alava E: 1q gain and CDT2 overexpression underlie an
aggressive and highly proliferative form of Ewing sarcoma. Oncogene
2011, 31:1287-1298.
doi:10.1186/1756-9966-31-24
Cite this article as: Mosakhani et al.: An integrated analysis of miRNA
and gene copy numbers in xenografts of Ewing’s sarcoma. Journal of
Experimental & Clinical Cancer Research 2012 31:24.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mosakhani et al. Journal of Experimental & Clinical Cancer Research 2012, 31:24
http://www.jeccr.com/content/31/1/24
Page 12 of 12